|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0979102A4
(en)
|
1997-04-30 |
2005-11-23 |
Enzon Inc |
DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
HU229888B1
(en)
|
1998-10-16 |
2014-11-28 |
Biogen Idec Ma Inc Cambridge |
Polymer conjugates of interferon betha-1a and uses
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
JP2004126818A
(ja)
|
2002-09-30 |
2004-04-22 |
Toshiba Corp |
電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
WO2005040219A1
(en)
|
2003-10-28 |
2005-05-06 |
Novo Nordisk A/S |
Laminin-5 gamma2-binding peptides, related compositions, and use thereof
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
JP5367982B2
(ja)
|
2004-04-16 |
2013-12-11 |
マクロジェニクス，インコーポレーテッド |
ＦｃγＲＩＩＢ特異的抗体とその利用法
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US20090208500A1
(en)
|
2005-06-03 |
2009-08-20 |
Genentech, Inc. |
Method of producing antibodies with improved function
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
PL2573114T3
(pl)
|
2005-08-10 |
2016-10-31 |
|
Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
|
|
EP1999470A4
(en)
|
2006-03-10 |
2009-08-19 |
Macrogenics Inc |
IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
|
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
WO2008124086A2
(en)
|
2007-04-05 |
2008-10-16 |
President And Fellows Of Harvard College |
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
|
|
CL2008003526A1
(es)
|
2007-11-30 |
2010-01-11 |
Medarex Inc |
Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
|
|
JP6157046B2
(ja)
|
2008-01-07 |
2017-07-05 |
アムジェン インコーポレイテッド |
静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
|
|
WO2010030671A1
(en)
|
2008-09-09 |
2010-03-18 |
University Of Medicine And Dentistry Of New Jersey |
Type i interferon antagonists
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
MY192182A
(en)
|
2009-06-26 |
2022-08-04 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
EA024629B1
(ru)
|
2009-12-09 |
2016-10-31 |
Институт Насьональ Де Ла Сант Де Ла Решерше Медикаль |
Моноклональные антитела, связывающие b7h6, и их применение
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
CA2813411C
(en)
|
2010-11-05 |
2016-08-02 |
Rinat Neuroscience Corporation |
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
WO2013037727A1
(en)
|
2011-09-13 |
2013-03-21 |
Deutsches Krebsforschungszentrum |
B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
EP2793947B1
(en)
|
2011-12-23 |
2021-02-03 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
ES2694180T3
(es)
|
2012-01-20 |
2018-12-18 |
Vib Vzw |
Citocinas de haz alfa-helicoidal mutantes dirigidas
|
|
WO2013169691A1
(en)
|
2012-05-07 |
2013-11-14 |
Trustees Of Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
MX369148B
(es)
|
2012-09-19 |
2019-10-30 |
Innate Pharma |
Agentes de unión kir3dl2.
|
|
EP3564259A3
(en)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及びイムノコンジュゲート
|
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
SG10202010429YA
(en)
|
2013-07-19 |
2020-11-27 |
Vib Vzw |
Targeting of cytokine antagonists
|
|
RS59756B1
(sr)
|
2013-08-08 |
2020-02-28 |
Cytune Pharma |
Kombinovana farmaceutska kompozicija
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
US9963509B2
(en)
|
2014-12-23 |
2018-05-08 |
Full Spectrum Genetics, Inc. |
Anti-B7H3 binding compounds and uses thereof
|
|
DK3313876T3
(da)
*
|
2015-06-23 |
2025-04-22 |
Innate Pharma |
Multispecifikke antigenbindende proteiner
|
|
AU2016284871B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific NK engager proteins
|
|
EP3397645B1
(en)
|
2015-12-28 |
2026-03-25 |
Innate Pharma |
Variable regions for nkp46 binding proteins
|
|
WO2017122130A1
(en)
|
2016-01-11 |
2017-07-20 |
Novartis Ag |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
|
WO2017165464A1
(en)
*
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
GEP20227398B
(en)
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
WO2017181001A1
(en)
|
2016-04-15 |
2017-10-19 |
Trustees Of Dartmouth College |
High affinity b7-h6 antibodies and antibody fragments
|
|
EP3565598A4
(en)
|
2017-01-03 |
2020-10-28 |
Trellis Bioscience, LLC |
NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
|
|
RU2019140833A
(ru)
|
2017-05-12 |
2021-06-15 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Применение антител против в7н3 для лечения злокачественных опухолей в центральной нервной системе
|
|
US10814011B1
(en)
|
2017-06-16 |
2020-10-27 |
Nantbio, Inc. |
Anti-B7-H4 antibodies and methods
|
|
JP7325341B2
(ja)
|
2017-07-11 |
2023-08-14 |
シンソークス，インク． |
非天然ヌクレオチドの組み込み及びその方法
|
|
KR20240141853A
(ko)
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
EP4029877B1
(en)
|
2017-08-03 |
2024-01-17 |
Amgen Inc. |
Interleukin-21 muteins and methods of treatment
|
|
CN109963591B
(zh)
|
2017-08-04 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
B7h3抗体-药物偶联物及其医药用途
|
|
CN112566934B
(zh)
|
2018-01-23 |
2024-09-17 |
奈斯科尔公司 |
B7-h4抗体及其使用方法
|
|
CN116693686A
(zh)
|
2018-02-11 |
2023-09-05 |
江苏豪森药业集团有限公司 |
抗b7-h4抗体、其抗原结合片段及其医药用途
|
|
BR112020016986A2
(pt)
|
2018-02-21 |
2021-03-02 |
Five Prime Therapeutics, Inc. |
formulações de anticorpo contra b7-h4
|
|
CN112004547A
(zh)
|
2018-02-26 |
2020-11-27 |
新索思股份有限公司 |
Il-15缀合物及其用途
|
|
KR20200144094A
(ko)
|
2018-03-02 |
2020-12-28 |
파이브 프라임 테라퓨틱스, 인크. |
B7-h4 항체 및 이의 사용 방법
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
KR20210025522A
(ko)
|
2018-06-25 |
2021-03-09 |
유니버시티 오브 워싱톤 |
강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
|
|
US12274759B2
(en)
|
2018-08-23 |
2025-04-15 |
Regents Of The University Of Minnesota |
Affibody proteins specific for B7-H3 (CD276)
|
|
CA3098930A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
CA3114474A1
(en)
|
2018-09-30 |
2020-04-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
US20210386826A1
(en)
|
2018-11-05 |
2021-12-16 |
Pfizer Inc. |
Combination for Treating Cancer
|
|
US12312406B2
(en)
|
2018-11-09 |
2025-05-27 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
|
|
WO2020097556A1
(en)
|
2018-11-09 |
2020-05-14 |
Nektar Therapeutics |
Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
|
|
WO2020102779A1
(en)
|
2018-11-16 |
2020-05-22 |
Albert Einstein College Of Medicine |
MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
|
|
WO2020140094A1
(en)
|
2018-12-27 |
2020-07-02 |
Gigagen, Inc. |
Anti-b7-h3 binding proteins and methods of use thereof
|
|
CN109851673B
(zh)
|
2019-01-22 |
2023-07-25 |
苏州旭光科星抗体生物科技有限公司 |
一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒
|
|
EP3923974A4
(en)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USE THEREOF
|
|
JP7737306B2
(ja)
*
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
US20220177550A1
(en)
|
2019-03-28 |
2022-06-09 |
Orionis Biosciences, Inc. |
Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
|
|
EP3980051A4
(en)
|
2019-06-05 |
2023-09-13 |
Asher Biotherapeutics, Inc. |
FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
WO2020252418A2
(en)
|
2019-06-14 |
2020-12-17 |
Cugene, Inc. |
Novel interleukin-2 variants for the treatment of cancer
|
|
TWI878355B
(zh)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
US20230112085A1
(en)
|
2020-01-30 |
2023-04-13 |
Apeximmune Therapeutics Inc. |
Anti-b7-h4 constructs and uses thereof
|
|
MX2022009936A
(es)
|
2020-03-18 |
2022-09-12 |
Genmab As |
Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
|
|
US20230183342A1
(en)
*
|
2020-04-06 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
|
|
WO2021247794A2
(en)
|
2020-06-03 |
2021-12-09 |
Regents Of The University Of Minnesota |
B7h3-targeting proteins and methods of use thereof
|
|
CN117980332A
(zh)
|
2020-08-18 |
2024-05-03 |
Abl生物公司 |
抗b7-h4/抗4-1bb双特异性抗体及其应用
|